Metagenomi Therapeutics, Inc.
MGXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M |
| Operating income | −$96.0M | −$88.9M | −$78.5M |
| Net income | −$87.9M | −$78.1M | −$68.3M |
| Total assets | $221.1M | $324.6M | $364.8M |
| Total liabilities | $62.5M | $89.7M | $149.7M |
| Equity | $158.6M | $234.9M | −$135.6M |
| EPS (diluted) | $-2.36 | $-2.36 | $-20.05 |
| Shares out. | 37.4M | 37.4M | 3.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −380.9%
- Net margin
- −348.5%
- Return on equity
- −55.4%
- Return on assets
- −39.7%
- Return on capital (ROCE)
- −48.4%
- Liabilities / assets
- 28.3%
- Debt / equity
- 0.39×
- Book value / share
- $4.24
- Revenue growth (YoY)
- −51.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.61distress
- Accruals / assets
- 0.5%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.8M | 10.1 | +1.1% |
| Apr 30, 2026 | 1.8M | 9.9 | -4.4% |
| Apr 15, 2026 | 1.9M | 10.9 | -13.7% |
| Mar 31, 2026 | 2.2M | 10.2 | +8.2% |
| Mar 13, 2026 | 2.0M | 6.2 | +3.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 11, 2026
- Results of operationsMar 5, 2026
- Amended charter or bylaws · Regulation FD disclosureJan 12, 2026
- Results of operations · Regulation FD disclosureNov 12, 2025
- Entered a material agreement · Terminated a material agreementOct 1, 2025
- Results of operations · Regulation FD disclosureAug 12, 2025
- Shareholder voteJun 11, 2025
- Other material eventMay 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.